Medications for Iron Deficiency Anemia
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Iron Deficiency Anemia.
Found 4 Approved Drugs for Iron Deficiency Anemia
Venofer
Generic Name
Venofer
Venofer
Generic Name
Venofer
Form: Injection
Method of administration: Intravenous, Intravitreal
FDA approval date: November 10, 2000
Classification: Parenteral Iron Replacement
Iron sucrose injection is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). ( 1 )
Injectafer
Generic Name
Carboxymaltose
Injectafer
Generic Name
Carboxymaltose
Form: Injection
Method of administration: Intravenous
FDA approval date: August 12, 2013
Classification: Parenteral Iron Replacement
Injectafer is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease. Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients ( 1 ): who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease. ( 1 )
Monoferric
Generic Name
Derisomaltose
Monoferric
Generic Name
Derisomaltose
Form: Injection
Method of administration: Intravenous
FDA approval date: January 16, 2020
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) MONOFERRIC is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron. ( 1 ) who have non-hemodialysis dependent chronic kidney disease. ( 1 )
Ferumoxytol
Brand Names
FeraBright, Feraheme
Ferumoxytol
Brand Names
FeraBright, Feraheme
Form: Injection
Method of administration: Intravenous
FDA approval date: July 13, 2009
Classification: Parenteral Iron Replacement
FERABRIGHT is indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. FERABRIGHT is an iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances